Cen is a shareholder of Jiangsu Hengrui Medicine, a Chinese producer of anti-cancer drugs. The company develops anti-tumor, anti-infective and painkiller drugs, and had revenue of 31.6 billion yuan ($4.4 billion) in 2025. He also owns a stake in Hansoh Pharmaceutical Group, a drug maker that trades publicly in Hong Kong.
The majority of Cen's wealth is derived from his 15% stake in Jiangsu Hengrui Medicine, a Chinese manufacturer of anti-cancer medicines. He owns his stake through a holding company, according to the company's 2025 annual report.
Cen also has a 15% stake in Hansoh Pharmaceutical Group, according to the company's 2025 interim report.
Liu Xiaohan, a spokesperson for the company, didn't respond to a request for comment on the net worth calculation.
Cen graduated from Zhejiang University majoring in pharmaceuticals in 1984.
His holding company Apex Medical was a founding shareholder of Hansoh Pharmaceutical Group in 2015, according to the company's prospectus for an initial public offering.
The company began publicly trading in Hong Kong in June 2019. Cen and Zhong Huijuan, chairwoman of the drug maker, are billionaires.